Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1489101 | 0.80 | ALDH1A1 (0.44) | ALDH1A1KDM4EMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL1489102 | 0.78 | ALDH1A1 (0.38) | ALDH1A1KDM4EMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL169909 | 0.76 | ALDH1A1 (0.37) | ALDH1A1 | |
| SCHEMBL612528 | 0.76 | ALDH1A1 (0.37) | ALDH1A1MEN1KMT2A | |
| SCHEMBL1257020 | 0.76 | TSHR (0.40) | ALDH1A1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL28514951 | 0.74 | ALDH1A1 (0.35) | ALDH1A1MEN1KMT2A | |
| SCHEMBL3453844 | 0.73 | ALDH1A1 (0.34) | ALDH1A1MEN1KMT2A | |
| Acetic Acid SCHEMBL28451523 | 0.73 | ALDH1A1 (0.34) | ALDH1A1KDM4EMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL986380 | 0.73 | ALDH1A1 (0.34) | ALDH1A1 | |
| SCHEMBL2550182 | 0.73 | ALDH1A1 (0.36) | ALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1392718-B1 | IMPROVED NATIVE CHEMICAL LIGATION WITH THREE OR MORE COMPONENTS | GENEPROT INC (CH) | 2006-01-11 | — | — | EP | claimed |
| US-20050064538-A1 | Native chemical ligation with three or more components | ASTRAZENECA PHARMACEUTICALS LP | 2005-03-24 | — | — | US | claimed |
| EP-1392718-A2 | IMPROVED NATIVE CHEMICAL LIGATION WITH THREE OR MORE COMPONENTS | Geneprot, Inc. (CH) | 2004-03-03 | — | — | EP | claimed |
| WO-2002098902-A2 | IMPROVED NATIVE CHEMICAL LIGATION WITH THREE OR MORE COMPONENTS | GENEPROT, INC. (CH) | 2002-12-12 | — | — | WO | claimed |
| US-7662914-B2 | Native chemical ligation with three or more components | AMYLIN PHARMACEUTICALS, INC. (US) | 2010-02-16 | — | — | US | disclosed |
| EP-1392718-B1 | IMPROVED NATIVE CHEMICAL LIGATION WITH THREE OR MORE COMPONENTS | GENEPROT INC (CH) | 2006-01-11 | — | — | EP | disclosed |
| US-20050064538-A1 | Native chemical ligation with three or more components | ASTRAZENECA PHARMACEUTICALS LP | 2005-03-24 | — | — | US | disclosed |
| EP-1392718-A2 | IMPROVED NATIVE CHEMICAL LIGATION WITH THREE OR MORE COMPONENTS | Geneprot, Inc. (CH) | 2004-03-03 | — | — | EP | disclosed |
| WO-2002098902-A2 | IMPROVED NATIVE CHEMICAL LIGATION WITH THREE OR MORE COMPONENTS | GENEPROT, INC. (CH) | 2002-12-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050064538-A1 | Native chemical ligation with three or more components | VIP, PTMS, FGB | ALDH1A1 2856/4885KDM4E 4363/4885MEN1 2565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.